Rongqing Li

机构：Kunming Medical University, First Affiliated Hospital of Kunming Medical University, Huainan Normal University · ORCID：0009-0003-6202-9407

发表论文 86 篇 · 总被引 1262 次 · h-index 19

代表论文

• Intracellular C5aR1 inhibits ferroptosis in glioblastoma through METTL3-dependent m6A methylation of GPX4 (2024 · Cell Death and Disease · 被引 32)
• RPLP2 activates TLR4 in an autocrine manner and promotes HIF-1α-induced metabolic reprogramming in hepatocellular carcinoma (2023 · Cell Death Discovery · 被引 23)
• ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease (2025 · Cell Death and Disease · 被引 22)
• Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial (2024 · Journal for ImmunoTherapy of Cancer · 被引 14)
• rTM reprograms macrophages via the HIF-1α/METTL3/PFKM axis to protect mice against sepsis (2024 · Cellular and Molecular Life Sciences · 被引 13)
• Revolutionizing medicine: Harnessing plant-derived vesicles for therapy and drug transport (2024 · Heliyon · 被引 12)